ASX Announcements 2010 ASX Announcements 2009 ASX Announcements 2008 ASX Announcements 2007 ASX Announcements 2006 ASX Announcements 2005 ASX Announcements 2004 ASX Announcements 2003 ASX Announcements 2002 Should you wish to view the report in your browser, you will need to have the Acrobat Reader installed. Please click on the icon (right) and follow the instructions. ASX Announcements 2004 Initiation of Phase IIa Trial of Antisense Drug for MS 21/12/2004   Animal Study Results Point to ATL1102's Potential For Asthma 20/12/2004   Appendix 3B - Exercise of Options 15/12/2004   Market Developments - New Treatment for MS 26/11/2004   Presentation - Institutional Life Science Forum in London 23/11/2004   ATL1101 for Psoriasis - Approval for "Proof of Concept" Trial 17/11/2004   Appendix 4C - Quarterly Cash Flow Report 27/10/2004   Appendix 3B - Exercise of Options 27/10/2004   ATL to present at Rodman & Renshaw 6th Annual Healthcare Conference 21/10/2004   Annual General Meeting 2004 - Presentation 20/10/2004   Annual General Meeting Results 20/10/2004   Antisense Therapeutics to establish Level 1 ADR Program 06/10/2004   Psoriasis Proof of Concept Study - Update 27/09/2004   Annual Report/Notice of AGM 21/09/2004   Appendix 3B - Exercise of Options 27/08/2004   2004 Financial Accounts - Appendix 4E 26/08/2004   Appendix 4C - Fourth Quarter Cash Flow Report 30/07/2004   Further Market Developments re Treatment for MS 28/07/2004   New Laboratory at Murdoch Childrens Research Institute 20/07/2004   Appendix 3b - Exercise of Options 09/07/2004   Investor Update - Market Developments re Treatment for MS 01/07/2004   Appendix 3Y - Change of Director's Interest 23/06/2004   Positive Results from Phase I Trial of ATL1102 for MS 08/06/2004   Presentation - BIO2004 Annual International Convention 07/06/2004   Appendix 3b - Exercise of Options 02/06/2004   Appendix 4c - Third Quarter Cash Flow Report 29/04/2004   ATL1103 Animal Study Results to be presented at International Symposium 20/04/2004   Appendix 3b - Exercise of Options 08/04/2004   Updated Corporate Presentation 16/03/2004   Investor Update March 2004 12/03/2004   Potential New Treatment for Growth & Sight Disorders 24/02/2004   Half Year Report 12/02/2004   Preliminary Phase I results - Neurosciences Conference Presentation 30/01/2004   Appendix 4C - Quarterly Cash Flow Report 30/01/2004   CEO Featured Guest on Biotech Today (US) Radio Program 14/01/2004